Results 71 to 80 of about 92,889 (88)

Evolving SARS-CoV-2 Vaccines: From Current Solutions to Broad-Spectrum Protection. [PDF]

Vaccines (Basel)
Qiao R, Li J, Gong J, Shao Y, Yu J, Chen Y, Lu Y, Yang L, Lin L, Hu Z, Wang P, Zhao X, Zhang W.   +12 more
europepmc   +1 more source

Protein Expression Platforms and the Challenges of Viral Antigen Production. [PDF]

Vaccines (Basel)
Sookhoo JRV, Schiffman Z, Ambagala A, Kobasa D, Pardee K, Babiuk S.   +5 more
europepmc   +1 more source

Tumor Antigens beyond the Human Exome. [PDF]

Int J Mol Sci
Emilius L, Bremm F, Binder AK, Schaft N, Dörrie J.   +4 more
europepmc   +1 more source

Personalized nanovaccines for treating solid cancer metastases. [PDF]

J Hematol Oncol
Feng T, Hu J, Wen J, Qian Z, Che G, Zhou Q, Zhu L.   +6 more
europepmc   +1 more source

Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer [PDF]

British Journal of Cancer, 2015
Background:We conducted a phase 1 trial in patients with locally advanced cervical cancer by injecting 0.5 ml of the CK2-antagonist CIGB-300 in two different sites on tumours to assess tumour uptake, safety, pharmacodynamic activity and identify the ...
Daniel F Alonso, I Garcia
exaly   +2 more sources

Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300

Biomedicines, 2021
Protein kinase CK2 has emerged as an attractive therapeutic target in acute myeloid leukemia (AML), an advent that becomes particularly relevant since the treatment of this hematological neoplasia remains challenging.
Mauro Rosales, George V Perez, Vladimir Besada   +2 more
exaly   +2 more sources

Mechanisms of Cellular Uptake, Intracellular Transportation, and Degradation of CIGB-300, a Tat-Conjugated Peptide, in Tumor Cell Lines [PDF]

Molecular Pharmaceutics, 2014
CIGB-300 is a cyclic synthetic peptide that induces apoptosis in malignant cells, elicits antitumor activity in cancer animal models, and shows tumor reduction signs when assayed in first-in-human phase I trial in patients with cervical tumors.
Yasser Perera, Daniel F Alonso, Silvio E Perea   +2 more
exaly   +2 more sources

CIGB-300 Peptide Targets the CK2 Phospho-Acceptor Domain on Human Papillomavirus E7 and Disrupts the Retinoblastoma (RB) Complex in Cervical Cancer Cells

Viruses, 2022
CIGB-300 is a clinical-grade anti-Protein Kinase CK2 peptide, binding both its substrate’s phospho-acceptor site and the CK2α catalytic subunit. The cyclic p15 inhibitory domain of CIGB-300 was initially selected in a phage display library screen for its
Om Basukala, Paola Massimi, Yasser Perera   +2 more
exaly   +2 more sources

Diastereomers of the Anticancer Peptide CIGB-300 with Altered β-Turn Structures [PDF]

International Journal of Peptide Research and Therapeutics
Purpose: The next-generation anti-tumor drug peptide CIGB-300, developed by the Center for Genetic Engineering and Biotechnology (CIGB), targets casein kinase 2 (CK2) and its substrates, implicating significant therapeutic potential in cancer ...
CARLOS S Perez, Hilda Garay, Yasser Perera   +2 more
exaly   +2 more sources

Sensitivity of tumor cells towards CIGB‐300 anticancer peptide relies on its nucleolar localization [PDF]

Journal of Peptide Science, 2012
CIGB-300 is a novel anticancer peptide that impairs the casein kinase 2-mediated phosphorylation by direct binding to the conserved phosphoacceptor site on their substrates.
Yasser Perera, Osvaldo Reyes, Daniel E Gomez   +2 more
exaly   +2 more sources